Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 2Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1Breast 1

Conditions

Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1

Interventions

Cyclophosphamide 296Cytarabine 261fludarabine phosphate 218Rituximab 195fludarabine 182Methotrexate 152Whole-Body Irradiation 140Mycophenolic Acid 124Azacitidine 122Tacrolimus 116Busulfan 110Filgrastim 104Granulocyte Colony-Stimulating Factor 98Etoposide 91Peripheral Blood Stem Cell Transplantation 90Dexamethasone 89Vincristine 88Melphalan 80Cyclosporine 74Lenalidomide 73Daunorubicin 70Decitabine 69Clofarabine 69Antilymphocyte Serum 67Calcium Dobesilate 61venetoclax 60Doxorubicin 58Imatinib Mesylate 57Alemtuzumab 56ibrutinib 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × molibresib × Other hematologic neoplasm × Clear all
NCT01943851 2024-10-01

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

GlaxoSmithKline

Phase 2 Completed
111 enrolled 71 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡